Clin2
NCT07548671Likely a fitNot yet recruiting

Enarodustat plus CsA for newly diagnosed low-severity aplastic anemia

Transfusion-dependent Non-severe Aplastic Anemia

Treatments studied

Part of Blood & lymphatic clinical trials.

This trial tests a new drug called enarodustat combined with an existing immune-suppressing medicine (CsA) to treat aplastic anemia—a rare blood disorder where your bone marrow doesn't make enough blood cells. The goal is to help your body produce more red blood cells without needing a bone marrow transplant.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
90 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are at least 18 years old
  • You have been diagnosed with transfusion-dependent non-severe aplastic anemia (low-severity form where you need blood transfusions)
  • Your hemoglobin (red blood cell protein) is below 90 g/L
  • You have not had a bone marrow transplant and are not a suitable candidate for one right now
  • Your liver and kidney function tests are less than twice the upper normal limit
  • You have an ECOG score of 2 or better (a measure of how well you can do daily activities)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07558434Not yet recruiting· Phase 2
New Treatment for Aplastic Anemia Using Four Medicines

This trial tests a combination of four medicines (cyclosporine, eltrombopag or hetrombopag, romiplostim, and supportive care) for newly diagnosed aplastic anemia—a serious blood disorder where the bone marrow stops making enough blood cells. The goal is to help your bone marrow work better and reduce your need for blood transfusions.

NCT06964971Not yet recruiting
Testing luspatercept for transfusion-dependent non-severe aplastic anemia

This trial tests if a drug called luspatercept can help people with a type of aplastic anemia that requires regular blood transfusions. It may reduce how often you need transfusions by boosting your body's own blood cell production.

Hangzhou, Zhejiang
NCT07741279Recruiting
Enarodustat for anemia in chronic kidney disease patients

This study tests a daily pill that helps people with chronic kidney disease and anemia make more red blood cells, which may reduce the need for other anemia treatments. It is for patients who are not on dialysis and do not plan to start dialysis or have a kidney transplant within the next six months.

Shanghai, Shanghai Municipality
NCT06725810Recruiting· Phase 4
Enarodustat for anemia in chronic kidney disease (not on dialysis)

This trial tests enarodustat, a pill for anemia, in people with chronic kidney disease who are not on dialysis. It aims to see if it can safely raise hemoglobin levels.

Shanghai, Shanghai Municipality
NCT07079579Not yet recruiting· Phase 4
Enarodustat for anemia in kidney disease patients not on dialysis

This trial tests whether starting enarodustat (a pill) at different doses can raise red blood cell levels and treat anemia in people with moderate-to-severe chronic kidney disease who are not yet on dialysis.

Beijing, Beijing Municipality
NCT06802055Recruiting· Phase 2
Sirolimus with or without cyclosporin for aplastic anemia

This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.

Beijing, Beijing Municipality

Hear when a new Transfusion-dependent Non-severe Aplastic Anemia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.